Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Moderate Buy” by Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned an average rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $16.50.

Several equities analysts have weighed in on NMRA shares. Royal Bank of Canada cut shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price objective for the stock from $29.00 to $4.00 in a research report on Thursday, January 2nd. Bank of America decreased their target price on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Needham & Company LLC reissued a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Neumora Therapeutics in a research report on Friday, February 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th.

Neumora Therapeutics Trading Up 3.0 %

NMRA stock opened at $1.71 on Friday. Neumora Therapeutics has a one year low of $1.60 and a one year high of $21.00. The firm has a 50-day moving average of $4.47 and a two-hundred day moving average of $9.40. The firm has a market capitalization of $276.27 million, a PE ratio of -0.91 and a beta of 2.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Neumora Therapeutics during the 4th quarter valued at about $61,000. PNC Financial Services Group Inc. bought a new position in Neumora Therapeutics during the fourth quarter valued at approximately $64,000. Quantbot Technologies LP acquired a new stake in Neumora Therapeutics in the fourth quarter valued at approximately $92,000. PEAK6 LLC bought a new stake in Neumora Therapeutics in the fourth quarter worth approximately $117,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Neumora Therapeutics during the 4th quarter worth $135,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.